

Non-alcoholic fatty liver disease in 2016

Townsend, Sarah; Newsome, Philip N

DOI:

[10.1093/bmb/ldw031](https://doi.org/10.1093/bmb/ldw031)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Townsend, S & Newsome, PN 2016, 'Non-alcoholic fatty liver disease in 2016', *British Medical Bulletin*, vol. 119, no. 1, pp. 143-56. <https://doi.org/10.1093/bmb/ldw031>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This is a pre-copyedited, author-produced PDF of an article accepted for publication in *British Medical Bulletin*. following peer review. The version of record Townsend, S. A., and Philip N. Newsome. "Non-alcoholic fatty liver disease in 2016." *British medical bulletin* 119.1 (2016): 143. is available online at: <http://dx.doi.org/10.1093/bmb/ldw031>

Checked 10/10/2016

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Non-Alcoholic Fatty Liver Disease in 2016

SA Townsend^{1,2}, Philip N Newsome^{1,2}

¹National Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham, UK.

²Liver Unit, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom

Word count 7157

Corresponding authors:

Dr Sarah Townsend

NIHR Birmingham Liver Biomedical Research Unit and Centre for Liver Research

5th Floor Institute of Biomedical Research

University of Birmingham

Birmingham, B15 2TT

UK

Tel: 0121 415 8700

Fax: 0121 415 8701

Email: s.a.townsend@bham.ac.uk

Professor Philip Newsome

NIHR Birmingham Liver Biomedical Research Unit and Centre for Liver Research

5th Floor Institute of Biomedical Research

University of Birmingham

Birmingham, B15 2TT

UK

Telephone: +44-121-415-8700

Fax: +44-121-415-8701

Email: P.N.Newsome@bham.ac.uk

Grant support: PNN and SAT are supported by the NIHR Birmingham Liver Biomedical Research Unit based at University Hospitals Birmingham and the University of Birmingham. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Abstract

Introduction

Non-alcoholic fatty liver disease is the commonest cause of liver disease worldwide, and is rapidly becoming the leading indication for liver transplantation.

Sources of data

Original articles, reviews and meta-analyses, guidelines.

Areas of agreement

NAFLD strongly correlates with obesity and insulin resistance; currently the best management strategy is weight loss and treatment of the metabolic syndrome.

Areas of controversy

Recent data suggest that the presence of fibrosis and not non-alcoholic steatohepatitis (NASH) is the predictor of clinical outcome.

Growing points

Many phase 2 and 3 trials are underway. Drugs hoped to be effective are obeticholic acid, elafibranor, glucagon-like peptide-1 analogues and CCR2/5 inhibitors.

Areas timely for developing research

Improved understanding of the pathophysiology of NAFLD should help to us identify which patients progress to significant liver disease and to develop therapies to target this population.

KEYWORDS: Non-alcoholic fatty liver disease, cardiovascular disease, NASH, fibrosis, metabolic syndrome, obesity, assessment, treatment.

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is the commonest cause of liver disease in Western countries, with an overall prevalence of 25% in the general population¹ rising to 70% in the obese population² and those who have type 2 diabetes mellitus^{2,3}. Moreover, the number of affected individuals is expected to increase over the forthcoming years⁴, in line with rising obesity due to the adoption of a high fat diet and sedentary lifestyle. In the US it has become the second commonest cause for liver transplantation and is likely to become the leading cause over the next 10 years⁵. This review will cover what is already known about the disease, current management strategies, and discuss areas of contention requiring further research and development.

PATHOPHYSIOLOGY

Free fatty acid (FFA) and hepatic triglyceride (TG) accumulation is a cardinal feature of NAFLD, and commonly occur in the setting of insulin resistance and obesity. Liver injury usually occurs in the presence of these features, mediated by inflammatory cytokines, mitochondrial dysfunction secondary to nutrient excess, and oxidative stress^{6,7}. The extent of hepatic inflammatory damage is also influenced by extrahepatic factors such as adipose tissue signalling⁷, the effect of gut microbiota⁸ and polymorphisms such as PNPLA3 and TLF6¹³ which are currently being explored.

In most patients the only response to obesity/insulin resistance is simple steatosis, or non-alcoholic fatty liver (NAFL), which is defined as steatosis $\geq 5\%$ and is believed to follow a relatively benign course. However, in a proportion of patients with steatosis¹ a more profound inflammatory liver damage occurs, termed non-alcoholic steatohepatitis (NASH), which is characterised by the presence of lobular inflammation and hepatocellular damage (ballooning). This carries a worse prognosis, with 40% developing progressive fibrosis leading to cirrhosis in 10-27%, and hepatocellular carcinoma (HCC) in about 4-27% of those with cirrhosis).^{1,9,10}

NAFLD is also an independent risk factor for cardiovascular disease (CVD) and diabetes mellitus⁶, and indeed, ischaemic heart disease and stroke are the leading cause of morbidity and mortality in patients with NAFLD⁹.

Areas of controversy

How important is NASH?

NASH reflects hepatocellular damage and often the commencement of fibrosis progression and yet several long term outcomes studies have suggested that it is fibrosis stage, rather than the presence of NASH or an elevated NAFLD activity score (NAS) that predict patient outcomes (see table 1)^{11,12}.

This may be a reflection of retrospective studies with insufficient power and/or it may be that NASH is a more dynamic entity which may spontaneously resolve as opposed to fibrosis, the presence of which is more intractable.

Growing points

It is likely that certain single nucleotide polymorphisms (SNPs) predispose some individuals to NAFLD. Genome wide association studies have identified several potentially important genetic variants; the polymorphism seen in patatin-like phospholipase domain-containing 3 (PNPLA3) and farnesyl diphosphate farnesyl transferase-1 (FDFT-1) appears to be most significant. A non-synonymous single nucleotide polymorphism, rs738409 (c.444 C>G, I148M) in palatin-like phospholipase domain-containing 3 (PNPLA3), encoding the adiponutrin protein, is linked to increased hepatic triglyceride content and increased severity of NASH and fibrosis in NAFLD¹³. Three other SNPs have been associated with the lobular inflammation phenotype: SNP rs1227756 on chromosome 10 in the COL13A1 (and collagen, type XIII, α 1) gene, rs6591182 on chromosome 11, and rs887304 on chromosome 12 in the EF-hand calcium binding domain 4B(EFCAB4B) gene, and

another SNP in transmembrane 6 superfamily member 2 (TM6SF2) (rs58542926 c.449 C>T, E167K) also has a strong association with NAFLD and disease progression to fibrosis and cirrhosis^{13,14}. It is therefore possible that in future we will be able to risk stratify patients according to the presence of genetic polymorphisms.

Recently, gut microbiota has been shown to have a potential role in the development of steatohepatitis and fibrosis in NAFLD. Lipopolysaccharides (LPS) from Gram negative gut micro flora are absorbed into intestinal capillaries and enter the portal system, activating toll-like receptors (TLRs) on hepatocytes, Kupffer cells and hepatic stellate cells and exerting a pro-inflammatory effect. The clearance of LPS is believed to be impaired in NAFLD, leading to a cascade of bacterial overgrowth, increased intestinal permeability and stimulation of inflammatory cytokines and chemokines, resulting in hepatic injury and fibrosis^{8,15}. There is particular interest in *Porphyromonas*, a gram negative coccus that has been associated with several components of the metabolic syndrome, as well as complications of chronic liver disease, but more work is needed to establish its exact role in the pathogenesis of human NASH⁸.

ASSESSMENT

In a clinical setting, it is important to identify those patients that are at risk of progressive liver fibrosis, as these individuals will require regular monitoring, lifestyle interventions and management of their cardiovascular risk factors. Notably, most subjects with NAFLD are generally asymptomatic, with the diagnosis often made following an incidental finding of a fatty liver on ultrasound scan (USS) or abnormal LFTs¹⁶. Figure 1 illustrates a suggested pathway for patients presenting with abnormal LFTs who are suspected to have NAFLD.

Serum markers

Levels of serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) are usually increased up to 1.5- to 4-fold but rarely exceed 5 times the upper limit of normal in the setting of NAFLD. Gamma glutamyl transpeptidase (GGT) and alkaline phosphatase levels may also be elevated, but the serum prothrombin time, bilirubin level and serum albumin level are normal, except in patients with NAFLD-associated cirrhosis. About a quarter of NAFLD patients may have antinuclear antibodies (ANA) in low titres (less than 1:320), and serum ferritin level may be raised in 20% to 50% of NAFLD patients, which is often associated with more advanced disease⁹. Plasma cytokeratin-18 (CK-18) is a filament protein in the liver, with caspase cleaved fragments released into blood stream following hepatocyte injury and apoptosis as seen in the setting of NASH. Levels of CK-18 fragments have been shown to correlate with histologically confirmed NASH in several groups (Area under the receiver operated curve (AUROC) of 0.83 and sensitivity of 77%), although it is not clear whether they have the precision to have a diagnostic role or help monitor response to therapy^{17,18}.

The enhanced liver fibrosis (ELF) test combines three candidate serum biomarkers for fibrosis; hyaluronic acid (HA), procollagen III amino terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP-1), which have been shown to correlate with the level of liver fibrosis seen histologically. A cut-off of 10.51 has been demonstrated to have a sensitivity of 100% and a specificity of 98% for detecting advanced fibrosis¹⁹; it is likely that ELF testing will be incorporated into upcoming UK guidelines to be used as a screening tool in the primary care setting.

Where NAFLD is detected, a liver screen is generally performed to exclude autoimmune, viral and genetic causes followed by an assessment to determine the presence of NASH or fibrosis in order to risk stratify the patient for progression of liver disease.

Imaging for steatosis and inflammation

Ultrasound scan (USS) is the commonest modality for diagnosing liver steatosis, as defined by hyper-echogenicity of the liver parenchyma relative to the kidney or spleen²⁰, and is widely used due to its simplicity, non-invasive nature and low cost²¹. It is however highly operator dependant, non-reproducible, and can be limited by abdominal gas or patient body habitus, but more importantly it is unable to distinguish simple steatosis from advanced fibrosis or cirrhosis²⁰

Use of the FibroScan® device with the controlled attenuation parameter (CAP) facility can also be used to assess hepatic steatosis. Ultrasound signals acquired by the FibroScan® are attenuated by liver fat which can be measured using a standard probe, giving a value between 100 and 400 dB/m²². One prospective study in 153 patients compared the percentage of steatosis on liver biopsy with CAP readings found that using a cut-off of 283 dB/m, the CAP was 76% sensitive, 79% specific, and had positive and negative predictive values of 87% and 64%, respectively. The AUROCs of the CAP for ≥5%, >33% and >66% steatosis in this study were 0.79, 0.76 and 0.70, respectively²³. A larger study by de Ledinghen et al compared CAP readings with histology in 440 patients and had similar finding grades of steatosis (>10%, >33% and >66%). AUROCs were 0.79 (95% CI 0.74-0.84, p<0.001), 0.84 (95% CI 0.80-0.88, p<0.001) and 0.84 (95% CI 0.80-0.88, p<0.001) respectively²⁴. In both studies only the M probe was used, and failure rate for those with a BMI >40kg/m² was 58.4%^{23,24}, although an XL probe is now available which has a lower failure rate and has similar accuracy in pilot studies²⁵.

Magnetic resonance imaging (MRI) techniques and magnetic resonance spectroscopy (MRS) have been shown to detect lower levels of steatosis (<5) as well as identify changes in fat content accurately. Magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF) is a novel, image-based modality that permits quantification of the entire fat content of the liver, and which correlates strongly with MR-spectroscopy measured liver fat and histologically-determined steatosis grade²⁶. Multi-parametric magnetic resonance (MR) imaging is another non-invasive technique

under development and involves a 3 stage process: T1 mapping for fibrosis/inflammation imaging, T2 mapping for liver iron quantification, and proton magnetic resonance spectroscopy (1H-MRS) for liver fat quantification. The results allow quantification of hepatic fibrosis, iron, and steatosis and in preliminary studies predict clinical outcomes in patients with chronic liver disease^{27,28}.

Imaging for fibrosis

Transient elastography (TE), through assessment of liver stiffness measurement (LSM) is widely available in most secondary or tertiary centres for the assessment of liver fibrosis²⁹. Several studies have provided moderate quality evidence for the diagnostic accuracy of transient elastography over a range of thresholds, and an XL probe has been validated for use in obese subjects. Wong et al demonstrated a sensitivity of 91% and a specificity of 75% in for the detection of significant (\geq F3) fibrosis using a cut off of $>7.9\text{kPa}$ ³⁰. The same group confirmed efficacy to detect \geq F3 fibrosis in those with a BMI ≥ 30 with a sensitivity and specificity of 90% using a cut off of 7.2kPa ³¹. Acoustic radiation force impulse (ARFI) imaging (ACUSON S2000™; Siemens Medical Solutions, Mountain View, CA, USA) is another ultrasound-based method for the assessment of liver stiffness based on the measurement of shear waves. Preliminary studies have shown that using a threshold of 4.24kPa , advanced fibrosis (stage 3 or 4) is detected with a sensitivity of 90% and specificity of 90%. It is comparable to transient elastography, and has the possible benefit that it can be undertaken during a routine US assessment^{32,33}.

Magnetic Resonance Elastography (MRE) has also been shown to be useful for the detection of significant fibrosis (stage 2 or above) and cirrhosis in all aetiologies of liver disease, including NAFLD^{34,35}. For detection of significant fibrosis MRE showed 100% sensitivity, 96.5% specificity, and 98.9% accuracy and 88.2% sensitivity, 91.1% specificity, and 93.5% accuracy for cirrhosis³⁴. The ability to provide a summative assessment of fibrosis of the liver is a major advantage, although as

with most elastography modalities the presence of significant inflammation can increase elastography readings³⁵.

Liver Biopsy

Liver biopsy remains the gold standard for both diagnosis and staging of disease, with NASH as defined by the presence of hepatocellular injury (ballooning, apoptosis/necrosis, presence of Mallory's hyaline, giant mitochondria), and inflammation (neutrophil and other inflammatory cell infiltrate)³⁶, being detected solely on histology. Several scoring systems exist to help quantify these histological changes, the commonest being the NASH Clinical Research Network (CRN) classification which encompasses the NAFLD activity score (NAS), which grades steatosis, lobular inflammation and hepatocellular ballooning, and a 0-4 score for liver fibrosis (see table 1). More recently, the steatosis, activity, fibrosis (SAF) score was proposed³⁷, which aims to accurately diagnose NASH and reduce inter-observer variability by further defining ballooning according to the size and shape of hepatocytes, and lobular inflammation according to the number of inflammatory foci per lobule. When used in the Fatty Liver Inhibition of Progression (FLIP) algorithm, patients can be further divided into those with NASH and those with simple steatosis³⁷. Liver histology remains the mainstay for outcomes in clinical trials and is required for seeking regulatory approval of new therapies.

Areas of controversy

Should we screen for NAFLD?

Many physicians advocate screening for NAFLD, and multiple methods have been proposed for this purpose, including imaging techniques such as USS, MRI and transient elastography, or using blood tests such as the fatty liver index or AST/ALT ratio. Early identification of patients with or at risk of NAFLD may facilitate beneficial changes in lifestyle and prompt aggressive treatment of features of

the metabolic syndrome, thereby reducing long term morbidity and mortality from both liver and cardiovascular disease. However, given the high prevalence of NAFLD (7-90% depending on the population and screening tool used)¹, limited treatment options, and the significant financial burden involved in screening, robust cost-effectiveness analyses are necessary to support this approach³⁸.

TREATMENT

Lifestyle modification

Unhealthy diets, such as those enriched in fructose, trans-fatty acids and saturated fat are believed to be associated with the development of NAFLD³⁹. Dietary sugars such as fructose are used as a substrate for lipogenesis leading to hepatic fatty infiltration, inflammation, and possibly fibrosis. Fat consumption, especially cholesterol, and trans or saturated fatty acids have also been shown to be steatogenic and seem to increase visceral adiposity⁴⁰. A recent review of dietary interventions in NAFLD suggested that restriction and modulation of simple and high glycaemic carbohydrates and total and saturated fats can improve metabolic parameters such as insulin resistance, decrease liver enzymes levels, and reduce the grade of steatosis, independent of weight loss⁴¹. However, few studies included liver biopsies, none were randomised control trials, and the authors were unable to conclude that benefits of dietary modification were truly independent of weight loss. Lifestyle modification, if successfully implemented, can result in weight loss with improvements in all histological aspects of NAFLD. A large prospective cohort study by Vilar-Gomez et al investigated the effect of various degrees of weight loss on liver histology in 261 patients, and found that improvements in inflammation (resolution of NASH or reduction in NAS score) correlated with the magnitude of weight loss⁴¹. Notably a greater degree of weight loss ($\geq 10\%$) was required for improvement in inflammation in those patients deemed higher risk at baseline (female sex, fasting glucose $>5.5\text{mmol/L}$, many ballooned cells at baseline, $\text{BMI} > 35$). Furthermore, those achieving $\geq 10\%$ weight reduction were also seen to have regression in fibrosis⁴¹. One of the major challenges with

lifestyle change once achieved is being able to sustain it for the longer-term which is lacking in studies thus far.

It is likely that a reduction in calorific intake to bring about weight loss is the most beneficial dietary modification in NAFLD, and there is little evidence to favour one dietary intervention over another.

In fact there are no RCTs, systematic reviews or comparative prospective cohort studies investigating diet alone, but several trials have shown that dietary intervention in addition to exercise appears to be the most effective⁴².

Exercise

Current obesity guidelines recommend 30 minutes of moderate exercise five times weekly⁴³ to aid weight loss and improve cardiovascular health. However, there is no consensus as to what the ideal duration or intensity is for NAFLD, and both moderate-intensity aerobic and resistance training have been shown to reduce intrahepatic lipid (IHL) independent of weight loss and dietary modification^{44,45}. One study also showed evidence for histological improvements in patients with NASH following a 24 week moderate intensity aerobic programme, although greater benefits were seen in those who also made dietary modifications⁴⁶. Most studies involve regimens of exercise for up to 60 minutes thrice weekly, much less than the guidelines for obesity. However, in most studies, the exercise was not monitored and so true level of participation is unknown⁴².

There is increasing interest in high-intensity interval training (HIIT), a modified form of sprint interval training using high intensity bouts of exercise followed by recovery periods, which has been proposed as a less time consuming alternative to continuous moderate intensity alternatives⁴⁷.

Studies have demonstrated at least equivalent if not greater improvements in cardiovascular fitness with HIIT compared to moderate intensity exercise in a broad range of populations, including those with obesity and the metabolic syndrome⁴⁸. A meta-analysis of HIIT also showed significant improvements in fasting glucose and glycated haemoglobin A1c (HBA1c) in this subgroup of volunteers⁴⁹, suggesting potential improvements in insulin sensitivity. A recent study of HIIT in

NAFLD showed a significant improvement in intrahepatic lipid, but no significant changes in measurements of insulin resistance (HBA1c, 2-hour insulin, HOMA2- β , HOMA2-S) following a thrice weekly 30 minute HIIT intervention for 12 weeks⁵⁰.

Diet supplements/probiotics

Consumption of omega-3 fatty acid has been found to be low in patients with NAFLD⁵¹, and there have been several randomised control studies of the benefits of omega 3 polyunsaturated fatty acid (PUFA) 'member.help@medicalprotection.org Many probiotic formulae have been studied in an attempt to target potential imbalance in gut microbiome described above, and have shown some success in improving hepatic steatosis, ALT levels and transient elastography scores¹⁵ in adults. Larger studies are needed to confirm these findings, and describe their role and ideal dosage in NAFLD.

Alcohol – to drink or not to drink?

Advice on alcohol consumption in the setting of NAFLD is controversial. Whilst there are data suggesting that modest consumption (1 unit/day) is associated with a reduced prevalence of NAFLD⁵⁵ and cardiovascular disease⁵⁶, other studies refer to the harmful synergy between alcohol and obesity⁵⁷. Pragmatically, most recommend consumption within standard limits with the exception of those with advanced fibrosis in whom abstinence is advised.

Caffeine

For some time, caffeine has been believed to be hepatoprotective, although its potential role in NAFLD has been unclear. A recent meta-analysis of four cross-sectional and two case control studies

concluded that caffeine from coffee was associated with reduced prevalence of hepatic fibrosis in patient NAFLD⁵⁸. More studies are needed before recommendations could be made regarding ideal daily consumption.

Pharmacotherapy

There are currently no approved pharmacotherapies for NAFLD, with the main focus being the management of components of the metabolic syndrome such as insulin resistance, hypertension and hyperlipidaemia. Hypertension and hyperlipidaemia should generally be managed according to local guidelines in the recognition that statins are not only safe in NAFLD but are associated with a reduced mortality^{12, 59}. There are no particularly favoured agents for control of hypertension, although previous studies had suggested that angiotensinogen receptor blockers may have additional anti-fibrotic effects⁶⁰.

A range of medications have been studied specifically in NAFLD with some proceeding into late phase trials. Metformin is the first line agent for T2DM, and reduces the risk of all diabetes-related end-points including microvascular disease, myocardial infarction, large vessel disease, and cardiovascular mortality, in addition to aiding weight loss⁶¹. Although studies have not demonstrated any improvements in liver enzymes or liver histology, there is epidemiological evidence to suggest it is associated with a reduced incidence of liver and non-liver malignancies including HCC in those with NASH cirrhosis by as much as 7%⁶².

Pioglitazone

Pioglitazone improves insulin sensitivity, reduces hepatic steatosis, inflammation, and to a lesser degree fibrosis⁶³ in patients with NASH, and has been shown to result in an 18% reduction in death,

myocardial infarction and stroke in patients with T2DM⁶⁴. The PIVENS trial assigned 247 non-diabetic adults with NASH to receive pioglitazone, vitamin E, or placebo, for 96 weeks. The primary outcome was a significant change in histologic features of NASH, as assessed with the use of the NASH CRN classification. Whilst pioglitazone did not meet its primary end-point⁶⁵, serum alanine and aspartate aminotransferase levels were reduced ($p < 0.001$), and there was a reduction in hepatic steatosis ($p < 0.001$) and lobular inflammation ($p = 0.004$), but not in fibrosis scores ($p = 0.12$ for pioglitazone). Subsequent meta-analyses has also demonstrated efficacy in inducing resolution of NASH⁶³. However, subjects in the PIVENS trial who received pioglitazone gained more weight than did those who received vitamin E or placebo⁶⁵, a side effect seen in several other studies.

Furthermore, concerns regarding the long-term safety of pioglitazone have limited its use. Two meta-analyses have found an increased risk of congestive cardiac failure, despite reductions in other cardiovascular mortality. In the study by Lincoff et al, heart failure was reported in 200 (2.3%) of pioglitazone-treated patients compared with 139 (1.8%) control patients (HR, 1.41; 95% CI, 1.14-1.76; $P = .002$)^{64,66}. Concerns have also been raised regarding the risk of bladder cancer, following a study demonstrating relative odds ratio of 4.30 (95% CI 2.82-6.52) for pioglitazone compared with other antidiabetic medications, based on adverse event reporting to the United States Food and Drug Administration (FDA) between 2004 and 2009⁶⁷. There is a possible reduction of bone density with pioglitazone; thiazolidinedione use causes PPAR- γ activation which increases bone resorption increases while decreasing bone formation, a significant concern as those with diabetes are already at increased risk of osteoporosis⁶⁸.

Liraglutide

Liraglutide is a GLP-1 receptor agonist approved for use in diabetes, which has been shown to induce improvements in peripheral, hepatic and adipose insulin resistance, alongside reductions in de novo lipogenesis⁶⁹. In a proof of concept RCT it met its primary end-point and induced resolution of NASH in both diabetic and non-diabetic patients⁷⁰, although further studies are needed to corroborate this

effect. Use of the higher 3 mg dose of liraglutide in an obese cohort without diabetes over 70 weeks, demonstrated significant weight loss in those on liraglutide versus placebo (63.2% vs 27.1% for 5% weight loss and 33.1% vs 10.6% for 10% loss, respectively)⁷¹. Side effects were minimal and the higher dose appeared well tolerated.

GFT505

PPARs are nuclear receptors that play key roles in the regulation of metabolism and inflammation. GFT505 is a new dual agonist of the PPAR α and δ receptors, and has been shown to improve lipid and glucose metabolism in type 2 diabetes mellitus (T2DM), and steatosis, inflammation and fibrosis in mouse models of NAFLD⁷². A small study (n=22) in an obese population has shown that GFT505 improved peripheral and hepatic insulin sensitivity, and significantly reduced Insulin-suppressed plasma free fatty acid concentrations, fasting plasma triglycerides and LDL cholesterol⁷³. Post-hoc analysis of a recently published randomised phase IIb study showed patients clearing NASH (as defined by disappearance of ballooning together with either disappearance of lobular inflammation or the persistence of mild lobular inflammation (score of 0 or 1) without worsening of fibrosis) with 120 mg oral elafibrinor (GFT505). When compared with placebo, improvement in NASH was more pronounced in those with NAS \geq 4, (19% vs 9%; p=0.013) compared with those with NAS \leq 4 (19% vs 12%; p=0.045), and it is likely that PPAR agonism will have a role in pharmacotherapy for NASH in the future^{74,75}.

Vitamin E

Vitamin E is an antioxidant and has potential mechanism to reduce oxidative stress in NASH. It is the most widely investigated antioxidant, and has been shown to improve steatosis and inflammation in several RCTs in both diabetic and non-diabetic children and adults^{76,77}. However, the trials have been heterogeneous, comparing different doses of vitamin E against various agents as well as

placebo, and in two studies the participants had lost weight, making it difficult to draw adequate conclusions. Despite meeting the primary end-point in the PIVENS trial, there are persisting concerns regarding the risk of prostate cancer and haemorrhagic stroke in higher doses^{78,79}, as well as reports of increased all-cause mortality⁸⁰. The SELECT study compared selenium vs vitamin E vs placebo for a primary outcome of Gleason grade ≥ 7 prostate cancer, and showed a relative risk of 17% with vitamin E. However, absolute risk was lower at 1.6 per 1000 person-years was 1.6 for vitamin E, and it is possible that identifiable SNPs affecting vitamin E metabolism may be responsible for the increased risk⁷⁸. A meta-analysis investigating the effect of vitamin E on the incidence stroke reported an increase in the relative risk of haemorrhagic stroke by 22%, while the risk of ischaemic stroke was reduced by 10%. Given the severity of outcomes following haemorrhagic stroke, the authors could not recommend the use of vitamin E⁷⁹. Despite the potential benefits for NASH, the longest prospective trial is 2 years⁷⁷, and given the long term concerns, the risks and benefits of therapy must be carefully discussed with patients in clinical practice.

Obeticholic acid

Obeticholic acid (OCA) is a synthetic variant of the natural bile acid chenodeoxycholic acid, a potent activator of the farnesoid X nuclear receptor, which down-regulates lipogenesis. A randomised, placebo-controlled trial in NAFLD (the FLINT study) demonstrated improvement in histological features of NASH (steatosis, hepatocyte ballooning, inflammation) as well as fibrosis⁸¹. Increased levels of low-density lipoprotein (LDL), and reduced high-density lipoprotein (HDL) were also seen in this group, which will need to be monitored in the ongoing phase III study. There was also a high incidence of pruritus (23%) which may be an important consideration for a condition with minimal symptoms⁸¹.

Bariatric surgery

Bariatric surgery offers an invasive but effective means of sustainable weight loss. There have been no RCTs investigating the benefits of bariatric surgery in NAFLD, but meta-analysis of cohort studies suggests an improvement in steatosis by 91.6%, steatohepatitis by 81.3%, and fibrosis, 65.5%,

following bariatric surgery⁸². Furthermore, improvements in insulin resistance, dyslipidaemia and other obesity related comorbidities have been demonstrated. No single technique is recommended for NAFLD but bypass procedures are believed to be the most effective for weight loss⁸³. RCTs and long term follow up studies are required to fully evaluate the risks and benefits of surgery over lifestyle modification and pharmacotherapy.

Growing points

LOXL2 antibody/inhibitors

LOXL2 is one of a family of enzymes involved in modifying the extracellular matrix, promoting cross-linking of cellular collagen, and fibrosis⁸⁴. Serum LOXL2 levels have been shown to correlate with fibrosis in NAFLD, and both an antibody and inhibitor have been developed, with phase 2b trials underway for the former (clinical trials.gov identifier: NCT01672866, NCT01672879).

Vascular adhesion protein-1

The adhesion molecule vascular adhesion protein-1 (VAP-1) is a membrane-bound amine oxidase that promotes leukocyte recruitment to the liver, and the soluble form (sVAP-1) accounts for most circulating monoamine oxidase activity, has insulin-like effects, and can initiate oxidative stress. An absence or blockade of functional VAP-1 in murine hepatic injury models has been shown to reduce inflammatory cell recruitment to the liver and attenuate fibrosis. Furthermore, serum sVAP-1 levels are elevated in patients with NAFLD compared with those in control individuals, and targeting VAP-1 is believed to have therapeutic potential for NAFLD and other chronic fibrotic liver diseases⁸⁵.

CCR2/CCR5 antagonist

The C-C chemokine receptor types 2 and 5 (CCR2 and CCR5), and their respective ligands, C-C chemokine ligand types 2 (CCL2/monocyte chemo attractant protein-1 [MCP-1]) and 5 (CCL5/RANTES) are involved in recruitment of inflammatory cells to the liver and activation of hepatic stellate cells which promote fibrosis⁸⁶. Inhibition of CCR2 or CCR5 in murine models of liver injury demonstrated reduction in fibrosis; an oral dual CCR2/CCR5 antagonist (Cenicriviroc), has now been developed and a phase IIb trial is currently underway⁸⁷.

Liver transplantation

Transplantation for NAFLD is rising, and with it, expertise in the selection and management of both graft and patient peri-operatively⁸⁸. Patients often have significant comorbidities, yet a recent meta-analysis showed a tendency towards death from cardiovascular disease or sepsis, but otherwise similar 5 year outcomes for NASH recipients compared with other aetiologies⁸⁹. Higher rates of renal dysfunction are observed in patients with NASH after transplantation, and therefore use of mycophenolate and lower serum levels of Tacrolimus are recommended⁹⁰.

CONCLUSIONS

NAFLD is the fastest growing cause for liver disease worldwide, and in the light of the obesity epidemic, shows no sign of waning. Liver steatosis alone is relatively benign, but the presence of fibrosis has significant implications for cardiovascular and liver related morbidity and mortality. The factors determining development of steatohepatitis and fibrosis are poorly understood, and warrant further investigation. Nevertheless, identifying those with NASH and fibrosis is crucial, as these patients should usually be managed within a secondary care setting, and may benefit from pharmacological and non-pharmacological interventions, regular modification of risk factors, and participation in clinical trials.

There are currently no non-invasive tests for steatohepatitis, but several for fibrosis. Currently, once patients at high risk group have been identified, management is focussed on encouraging weight loss and managing features of the metabolic syndrome, in an attempt to halt progression of the disease and reduce cardiovascular mortality. Exercise and weight loss remain the most effective strategy for disease management, but is limited by the ability to sustain lifestyle changes in this population group. Identifying dietary and exercise regimens that are the easiest to adopt and lead to longstanding lifestyle reform will improve liver and cardiovascular outcomes. These would ideally be tailored to individual needs and abilities, but this is a resource-heavy approach, and may not be practicable in most healthcare systems.

Trials for pharmacological agents have historically been limited by small study cohort sizes, a dearth of high quality studies, and concerns regarding efficacy and side effects. However, there is now multiple large phase II/III RCT in progress with both new and existing agents, with the FDA assigning breakthrough designation for several of them in light of the significant clinical unmet need in NASH. . NAFLD is a highly complex condition with multiple parallel pathways and thus it is likely that therapy will be personalised and consist of multiple therapies.

References

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global Epidemiology of Non-Alcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence and Outcomes. *Hepatology*. 2015 Dec 28. doi: 10.1002/hep.28431. [Epub ahead of print]
2. Smits MM, Iannou GN, Boyko EJ, et al. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. *J Gastroenterol. Hepatol* 2013; **28**, 664-670.
3. Szczepaniak LS, Nurenburg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. *Am J Physiol Endocrinol Metab* 2005; **288**: 462-468.
4. Visscher TLS, Heitmann BL, Rissanen A, et al. A break in the obesity epidemic? Explained by biases or misinterpretation of the data? *International Journal of obesity* 2005; **39**; 189-198.
5. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. *Gastroenterology* 2015; **148**: 547–555.
6. Haas JT, Francque S, Staels B. Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. *Annu Rev Physiol* 2015; **78**: 18.1-18.25.
7. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. *QJM* 2010; **103**: 71–83.
8. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. *Nature* 2012; 482: 179-85.
9. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology* 1999; **30**: 1356-1362.
10. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. *Hepatology* 2010; **51**: 1820–1832.
11. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology*. 2015; **61**: 1547-54.
12. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2015; **149**: 389-97.
13. Anstee QM, Seth D, Day CP. Genetic Factors That Affect Risk of Alcoholic and Non-Alcoholic Fatty Liver Disease. *Gastroenterology*. (2016) doi: 10.1053/j.gastro.2016.01.037.
14. Chalasani N, Guo X, Loomba R, et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. *Gastroenterology* 2010; **139**: 1567-176.
15. Kelishadi R, Farajian S, and Mirlohi M. Probiotics as a Novel Treatment for Non-Alcoholic Fatty Liver Disease; A Systematic Review on the Current Evidences. *Hepat Mon*. 2013;13:e7233.
16. Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. *JHep* 2012; **56**: 234–240.
17. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. *Hepatology* 2009 Oct; **50**: 1072-8.
18. Baršić N, Lerotić I, Smirčić-Duvnjak L, Tomašić V, and Duvnjak M. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. *World J Gastroenterol*. 2012 Aug 14; **18**: 3945–3954.

19. Nobili V, Parkes J, Bottazzo G, *et al.* Performance of ELF Serum 36 Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease. *Gastroenterology* 2009; **136**: 160-167.
20. Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty liver: imaging patterns and pitfalls. *Radiographics* 2006;**26**: 1637-53.
21. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. *Clin Liver Dis* 2007; **11**: 37-54.
22. M. Sasso, M. Beaugrand, V. de Ledinghen, C. Douvin, P. Marcellin, R. Poupon, *et al.* Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. *Ultrasound Med Biol* 2010; **36**: 1825–1835.
23. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, Duarte-Rojo A, Wong D, Crotty P, Elkashab M Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. *Liver Int.* 2012; **32**: 902-10.
24. de Lédighen V, Vergniol J, Capdepon M, *et al.* Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. *J Hepatol* 2014; **60**: 1026-1031.
25. Sasso M, Audière S, Kemgang A *et al.* Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy. *Ultrasound Med Biol* 2016; **42**: 92-103.
26. Nouredin M, Lam J, Michael R. Peterson MR, *et al.* Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials *Hepatology* 2013; **58**: 1930-1940.
27. Banerjee R, Pavlides M, Tunncliffe EM, *et al.* Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. *J Hepatol* 2014; **60**: 69–77.
28. Pavlides M, Banerjee R, Sellwood J, *et al.* Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. *J Hepatol.* 2016; **64**: 308-15.
29. Brener S. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. *Ont Health Technol Assess Ser* 2015; **15**: 1-45..
30. Wong VW1, Vergniol J, Wong GL, *et al.* Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. *Hepatology* 2010; **51**: 454-62.
31. Wong VW, Vergniol J, Wong GL, *et al.* Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. *Am J Gastroenterol* 2012; **107**: 12:1862-71.
32. Palmeri ML, Wang MH, Rouze NC, Abdelmalek MF, Guy CD, Moser B, *et al.* Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. *J Hepatol.* 2011; **55**: 666-72.
33. Yoneda M, Suzuki K, Kato S, *et al.* Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. *Radiology.* 2010;**256**: 640-7.
34. Venkatesh SK, Yin M, Takahashi N, Glockner JF, Talwalkar JA, Ehman RL. Non-invasive detection of liver fibrosis: MR imaging features vs. MR elastography. *Abdom Imaging* 2015; **40**: 766-75.
35. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, and Ehman RL. Early Detection of Nonalcoholic Steatohepatitis in Patients with Nonalcoholic Fatty Liver Disease by Using MR Elastography. *Radiology* 2011; **259**: 749–756.
36. Hubscher SG. Review. Histological assessment of non-alcoholic fatty liver disease. *Histopathology.* 2006; **49**: 450–465.

37. Bedossa P; FLIP Pathology Consortium Hepatology. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. *Hepatology* 2014; **60**:565-75.
38. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 2012 Jun;**142**:1592-609.
39. Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence. *World J Gastroenterol* 2011; **17**: 3377-3389.
40. Ferolla SM, Silva LC, Ferrari MLA, et al. Dietary approach in the treatment of nonalcoholic fatty liver disease. *World J Hepatol* 2015; **28**: 2522-2534.
41. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. *Gastroenterology* 2015; **149**: 367-378.
42. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. *JHepatol* 2012; **57**: 157-166.
43. National Institute for Clinical Excellence (NICE). Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children (2006).
44. Johnson N, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. *Hepatology* 2009; **50**: 1105-1112.
45. Hallsworth K, Fattakhova G, Hollingsworth KG. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. *Gut* 2011; **60**: 1278-1283.
46. Eckard C, Cole R, Lockwood J, et al. Prospective histopathologic evaluation of lifestyle modification in non-alcoholic fatty liver disease: a randomised trial. *Therapeutic Advances in Gastroenterology* 2013; **6**: 249-259.
47. Gibala MJ. High-intensity interval training: a time-efficient strategy for health promotion? *Curr Sports Med Rep* 2007; **6**: 211-3.
48. Gibala MJ, Little JP, Macdonald MJ and Hawley JA. Physiological adaptations to low-volume, high-Intensity interval training in health and disease. *J.Physiol.* 2012; **590**: 1077-1084.
49. Jelleyman C, Yates T, O'Donovan G, et al. The effects of high-intensity training on glucose regulation and insulin resistance: a meta-analysis. *Obes Rev.* 2015; **16**: 942-61.
50. Hallsworth K, Thoma c, Hollingsworth K, et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: A randomised controlled trial. *Clin Sci* 2015; **129**: 1097-105.
51. Araya J, Rodrigo R, Videla LA, et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. *Clin Sci* 2004; **106**: 635-643.
52. Masterton GS, Plevieris JN, Hayes PC. Review article: Omega-3 fatty acids - A promising novel therapy for non-alcoholic fatty liver disease. *Aliment Pharmacol* 2010 **31**:679-92.
53. Parker HM, Johnson A, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. *JHepatol* 2012; **56**: 944-951.
54. Pacifico L, Bonci E, Di MM, Versacci P, Andreoli G, Silvestri LM et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. *NMCD* 2015; **25**:734-741

55. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of Nonalcoholic Fatty Liver Disease in the United States: The Third National Health and Nutrition Examination Survey, 1988–1994. *Am J Epidemiol* 2013; **178**: 38–45.
56. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. *BMJ* 2011;342:d671.
57. Hart CL, Morrison DS, Batty GD, Mitchell RJ, Smith GD. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. *BMJ* 2010; **340**: c1240.
58. Shen H, Rodrigue AC, Shiani A, et al. Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis. *Therap Adv Gastroenterol* 2016; **9**: 113-20.
59. Tziomalos K, Athyros VG, Paschos P, Karagiannis A. Nonalcoholic fatty liver disease and statins. *Metabolism* 2015; **64**: 1215-23.
60. Musso G, Gambino R, Cassader M, Pagano G. A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease. *Hepatology* 2010; **52**: 80-104.
61. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. *Ann Intern Med.* 2016 Apr 19. doi: 10.7326/M15-2650.
62. Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. *Gut* 2013; **62**: 606-15.
63. Boettcher E, Csako G, Pucino F, Wesley R, Loomba R: Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2012; **35**: 66–75.
64. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA* 2007; **298**: 1180–1188.
65. Sanyal AJ, Chalasani N, Kowdley KV, et al: Pioglitazone, vitamin E, or placebo for non-alcoholic steatohepatitis. *N Engl J Med* 2010; **362**: 1675–1685.
66. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. *Lancet* 2007; **370**:1129–1136.
67. Piccinni C, Motola D, Marchesini G, Poluzzi E: Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. *Diabetes Care* 2011; **34**: 1369–1371.
68. Lecka-Czernik B: Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. *Curr Osteoporos Rep* 2010; **8**: 178–184.
69. Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. *J Hepatol.* 2016; **64**:399-408.
70. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 2016; **387**: 679-690.
71. Astrup A, Carraro R, Finer N. Safety, tolerability and sustained weight loss over 2 years with the once daily human GLP-1 analog, liraglutide. *Int J Obes.* 2012; **36**: 843-854.
72. Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *Hepatology.* 2013; **58**:1941-52.

73. Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. *Diabetes Care*. 2013; **36**: 2923-30.
74. Ratziu V, Harrison S, Francque S, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. *Gastroenterology* 2016. DOI: <http://dx.doi.org/10.1053/j.gastro.2016.01.038>
75. Newsome PN. Entering the GOLDEN age for therapies in NASH. *Gastroenterology* 2016; **150**: 1073–1076.
76. Lavine JE, Schwimmer JB, Van Natta ML, et al: Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. *JAMA* 2011; **305**: 1659–1668.
77. Sumida Y, Naito Y, Tanaka S, et al. Long-term (≥ 2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis. *Hepatology* 2013; **60**: 1445-1450.
78. Chan JM, Darke AK, Penney KL, et al. Selenium or Vitamin E-related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. *Cancer Epidemiol Biomarkers Prev*. May 2016; doi: 10.1158/1055-9965.EPI-16-0104.
79. Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T: Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. *BMJ* 2010; **341**:c5702.
80. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* 2005; **142**: 37-46.
81. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet* 2015; **385**: 956-65.
82. Mumtaz RR, Kasturi KS, Chennareddygar S, Sood GK. Effects of bariatric surgery on non-alcoholic fatty liver disease: systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2008; **6**:1396–402.
83. Hafeez S and Ahmed MH. Bariatric Surgery as Potential Treatment for Nonalcoholic Fatty Liver Disease: A Future Treatment by Choice or by Chance? *Journal of Obesity*. J Obes. Published online 2013 January 29. doi: 10.1155/2013/839275.
84. Moon HJ, Finney J, Ronnebaum T, Mure M. Human lysyl oxidase-like 2. *Biorganic chemistry* 2014; **57**: 231-241.
85. Weston CJ, Shepherd EL, Claridge LC, et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. *J Clin Invest* 2015 Feb; **125**: 501-20.
86. E. Seki, S. De Minicis, G.Y. Gwak, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. *J. Clin. Invest* 2009; **119**: 1858–1870.
87. Friedman S, Sanyal A, Goodman Z et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. *Contemporary Clinical Trials* 2016; **47**:356–365.
88. Newsome PN, Allison ME, Andrews PA. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. *Gut* 2012; **61**: 484-500.
89. Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2014; **12**: 394–402.
90. Houlihan DD1, Armstrong MJ, Davidov Y, et al. Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens? *Liver Transpl* 2011; **17**: 1292-8.

Table 1. NASH CRN histological scoring system.

NAFLD Activity Score (NAS) (0–8)

Sum of scores for steatosis, lobular inflammation and hepatocellular ballooning

Steatosis (0–3)

0 = <5% hepatocytes involved

1 = 5–33% hepatocytes involved

2 = 33–66% hepatocytes involved

3 = >66% hepatocytes involved

Lobular Inflammation (0–3)

0 = none

1 = <2 foci per ·200 field

2 = 2–4 foci per ·200 field

3 = >4 foci per ·200 field

Hepatocyte ballooning (0–2)

0 = none

1 = few ballooned cells

2 = many cells / prominent ballooning

Score

≥5 Probable or definite NASH

3–4 Uncertain

≤2 Not NASH

Fibrosis stage

1 Perisinusoidal or periportal

1a = Mild, zone 3, perisinusoidal

1b = Moderate, zone 3, perisinusoidal

1c = Portal / periportal fibrosis only

2 Perisinusoidal and portal / periportal fibrosis

3 Bridging fibrosis

4 Cirrhosis
